Spanish research led by C.I. Andersson Vila with the Hospital Clinic Barcelona, Department of Hematology reveals that real-world safety of CART-19 treatments are similar to adverse event rates documented in clinical trials.
The Spanish single-center study revealed that 30% of CART-19 infusions administered at their hospital resulted in cardiovascular adverse events (AEs) and 30% prompted the transfer of patients to intensive care as reported in Clinical Oncology. The Spanish team, led by Dr. Andersson Vila, reported their findings at the 2019 European Society for Medical Oncology Congress (abstract CN89).
The study team retroactively examined medical records of adults who received a total of 27 CART-19 treatments at the Spanish hospital between January 2017 and April 2019. A majority of the patients in this RWE study included those treated for acute lymphocytic leukemia (ALL).
The Observations of the Real-World Study
The real-world-based research was inspired by the desire to better understand the challenges associated with CART-19 treatment. CART-19 has helped save lives. But challenges associated with this advanced treatment include adverse events such as cytokine release syndrome (CRS). The most common AE was hypertension (29.6%) then Tachycardia (22.2%) and headache (11.1%). Approximately 30% of the time patients required transfer to the ICU after treatment. 22% of the infusions thereafter required treatment with tocilizumab (Actemra, Genentech/Roche) to manage CRS. A low incidence of neurologic and gastrointestinal AEs was observed. Dr. Andersson Vila’s team found that 85.2% of the time patients experienced a fever after the CART-19 infusion.
C.I. Andersson Vila, Hospital Clinic BarcelonaCall to Action: Interested in CART-19 real-world findings, perhaps reach out to and connect with Dr. Andersson Vila.Source: Clinical Oncology News